Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
So far more than 1000 trials are currently ongoing with gene and cell therapies. Cure is no longer a dream for several monogenic disorders. However there is still uncertainty on how those products will be accessed by patients and at what price. This book aim to show how the regulatory environment has evolved to analyze and review those therapies.
So far more than 1000 trials are currently ongoing with gene and cell therapies. Cure is no longer a dream for several monogenic disorders. However there is still uncertainty on how those products will be accessed by patients and at what price. This book aim to show how the regulatory environment has evolved to analyze and review those therapies.
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.
Mondher Toumi is M.D. by training, M.Sc. in Biostatistics, and in Biological Sciences (option pharmacology) and Ph.D. in Economic Sciences. Mondher Toumi is Professor of Public Health at Aix-Marseille University. After working for 12 years as Research Manager in the department of pharmacology at the University of Marseille, he joined the Public Health Department in 1993. In 1995 he embraces a carrier in the pharmaceutical industry for 13 years. Toumi was appointed Global Vice President at Lundbeck A/S in charge of health economics, outcome research, pricing, market access, epidemiology, risk management, governmental affairs and competitive intelligence. In 2008, he founded Creativ-Ceutical, an international consulting firm dedicated to support health industries and authorities in strategic decision-making. In February 2009 he was appointed Professor at Lyon I University in the Department of Decision Sciences and Health Policies. The same year, he was appointed Director of the Chair of Public Health and Market Access. He launched the first European University Diploma of Market Access (EMAUD) an international course already followed by almost 350 students. Additionally, he recently created the Market Access Society to promote education, research and scientific activities at the interface of market access, HTA, public health and health economic assessment. He is editor in Chief of the Journal of Market Access and Health Policy (JMAHP) which was just granted PubMed indexation. Toumi is also visiting Professor at Beijing University (Third Hospital). He is a recognized expert in health economics and an authority on market access and risk management. He has more than 250 scientific publications and communications, and has contributed to several books.
Eve Hanna is global pricing and market access consultant at Creativ-ceutical, where she engages in several types of market access research. Eve is PhD in Health economics, pharmD, and holds a master's degree in pharmaco-epidemiology. She has successfully completed the European Market Access University Diploma (EMAUD) and is currently senior lecturer in health technology assessment (HTA) and Market Access at EMAUD. Her area of expertise is cell and gene therapies HTA, funding and market access; she has several publications in peer-reviewed journals and major conferences all focused on gene and cell therapies. Eve has contributed to three books mainly on orphan drugs topics. During her five years of experience in the field of market access, Eve has acquired proficient knowledge on HTA, pricing and reimbursement processes and health policy at global level.
Inhaltsangabe
Chapter 1 Introduction to cell and gene therapies concepts and definitions in the US and EU .................................................... 1 Chapter 2 Cell and gene therapies: genuine products and potential for dramatic value ........................................... 19 Chapter 3 Cell and gene therapies: regulatory aspects in the US and EU ............................................................................ 31 Chapter 4 The need for new HTA reference case for cell and gene therapies ............................................................................ 59 Chapter 5 How to mitigate uncertainties and HTA risk-averse attitude? ............................................... 91 Chapter 6 Cell and gene therapies funding: challenges and solutions for patients' access ........................................ 101 Chapter 7 Conclusion ................................................................................ 129
Chapter 1 Introduction to cell and gene therapies concepts and definitions in the US and EU .................................................... 1 Chapter 2 Cell and gene therapies: genuine products and potential for dramatic value ........................................... 19 Chapter 3 Cell and gene therapies: regulatory aspects in the US and EU ............................................................................ 31 Chapter 4 The need for new HTA reference case for cell and gene therapies ............................................................................ 59 Chapter 5 How to mitigate uncertainties and HTA risk-averse attitude? ............................................... 91 Chapter 6 Cell and gene therapies funding: challenges and solutions for patients' access ........................................ 101 Chapter 7 Conclusion ................................................................................ 129
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Shop der buecher.de GmbH & Co. KG Bürgermeister-Wegele-Str. 12, 86167 Augsburg Amtsgericht Augsburg HRA 13309
